Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study

F. Zanaboni, B. Grijuela, S. Giudici, G. Cormio, L. Babilonti, F. Ghezzi, G. Giorda, G. Scambia, M. Franchi, M. Lorusso, A. Ditto, D. Lorusso, F. Raspagliesi

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: The aim of this phase II multicentric study was to evaluate the efficacy and toxicity of neo-adjuvant chemotherapy with weekly topotecan and cisplatin in locally-advanced squamous cervical cancer. Patients and methods: From November 2008 to January 2011, 92 patients met the inclusion criteria and were enrolled. Eligibility criteria were: squamous or adenosquamous cervical cancer; clinical stages IB2, IIA, IIB; Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2; neutrophils ≥ 1500/μL; platelets ≥ 100,000/μL, normal renal and liver function. Treatment consisted of six courses of weekly topotecan (2 mg/m2) and cisplatin (40 mg/m 2). All responsive and stable patients were submitted to radical surgery, while progressed cases underwent definitive radiotherapy ± chemotherapy. Primary end-point was evaluation of efficacy and toxicity. All patients are evaluable for toxicity and efficacy. Results: Ninety-six percent of patients completed the six planned courses of chemotherapy, and 95% of courses were administered at a full dose and without interruption or delay. Mean age was 49 years (35-64 years). FIGO Stage distribution was 30 IB2, 13 IIA and 49 IIB. Treatment was well tolerated and no death occurred. G3-G4 haematological toxicity was observed in 28% of patients (5% out of cycles). Support therapies (blood transfusions and/or erythropoietin and/or Granocyte-Colony Stimulating Factor) were given to 24% of patients. Clinical response rate was 77%. The nine progressed cases were irradiated, while the remaining 83 patients were submitted to radical surgery. An overall pathologic response was observed in 67% of patients, with an optimal response rate of 32% and a disease downstage in 57% of patients. Nodal metastases occurred in 36% of patients. Adjuvant therapy (radiotherapy and or chemotherapy) was prescribed in 55% of patients, because of lymph node metastases, parametrial or vaginal involvement or cut-through margins. Median follow-up was 18 months: 76% of patients are alive and free from recurrence, 24% of patients relapsed and 13% died. Conclusions: Weekly topotecan and cisplatin showed an acceptable toxicity profile; the promising response rate warrants further investigation.

Original languageEnglish
Pages (from-to)1065-1072
Number of pages8
JournalEuropean Journal of Cancer
Volume49
Issue number5
DOIs
Publication statusPublished - Mar 2013

Keywords

  • Cervical cancer
  • Cisplatin
  • Neoadjuvant therapy
  • Topotecan
  • Treatment efficacy
  • Treatment toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study'. Together they form a unique fingerprint.

Cite this